Final analysis of MAIA in 737 transplant-ineligible patients with newly diagnosed multiple myeloma: daratumumab plus lenalidomide/dexamethasone gave median OS of 90.3 vs 64.1 months with lenalidomide/dexamethasone alone (HR 0.67); deaths from adverse events 12% vs 11%.
RCTn = 737
Facon et al. Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis